Login to Your Account

KSQ emerges with $76M to prove its mettle in gene play

By Marie Powers
News Editor

Monday, October 2, 2017

Looking to one-up early stage entries in harnessing CRISPR technology, 2-year-old KSQ Therapeutics burst onto the biopharma scene with $76 million across two financing rounds and an aspiration to pioneer what it called "high-confidence" drug development.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription